HDACi and bone in Multiple myeloma

多发性骨髓瘤中的 HDACi 和骨

• 批准号: nhmrc : GNT1070880
• 负责人: Dr Melissa Cantley
• 金额: $ 30.46万
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/hdaci-bone-multiple-myeloma/1344995
• 关键词: HDACi; bone; Multiple; myeloma

Multiple myeloma (MM) is an incurable hematological malignancy with 1,400 people diagnosed each year. Severe bone loss occurs in up to 90% of these patientssignificantly impacting on quality of life resulting in severe bone pain and bone lesions that fail to heal. This project proposes that a novel histone deacetylase inhibitor could provide an appropriate therapeutic strategy that inhibits tumor growth and prevents bone loss whilst also promoting bone repair.

多发性骨髓瘤(MM)是一种无法治愈的血液系统恶性肿瘤，每年有1,400人确诊。这些患者中高达90%会发生严重的骨丢失，严重影响生活质量，导致严重的骨痛和无法愈合的骨损伤。该项目提出，一种新型的组蛋白去乙酰酶抑制剂可以提供一种适当的治疗策略，在促进骨修复的同时抑制肿瘤生长和防止骨丢失。